Brazil approves first generics of liraglutide, expanding access to GLP-1 treatments

Brazil’s health regulator Anvisa has authorised the registration of two liraglutide-based generics, paving the way for broader access to essential treatments for type 2 diabetes and obesity, though market entry remains subject to pricing and prescription regulations. Brazil’s health regulator…













